A Phase 3 interventional study of Ipilimumab and Oxaliplatin in Metastatic Colorectal Cancer, sponsored by Bristol-Myers Squibb. Active, not recruiting at 157 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ipilimumab in Colorectal Neoplasms — 5 open to participants now, 7 under way, 1 of them phase 3. Ipilimumab · Colorectal Neoplasms.
Among the 14 studies testing ipilimumab in Colorectal Neoplasms, this one has the largest enrollment, is one of 3 that started in 2019, is the only one in phase 3, and was the 4th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 14 studies testing ipilimumab in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
GERCOR - Multidisciplinary Oncology Cooperative Group · Sites in France
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–70
Centre Georges Francois Leclerc · Sites in France
Ages 18+
Fudan University · Sites in China
Ages 18+
By country, each count listing its studies:
Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ipilimumab is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 1
First in 2017; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 839 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 14 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 16th registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
2 of the studies testing ipilimumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04730544GERCOR - Multidisciplinary Oncology Cooperative GroupTwo Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | 2027-04 |
| NCT07587827Centre Georges Francois LeclercStudy Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ipilimumab in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab
Biological: Ipilimumab · Biological: Nivolumab
Participants in Arm C would be allowed to receive Nivolumab + Ipilimumab if they progress
Drug: Oxaliplatin · Drug: Leucovorin · Drug: Fluorouracil · Drug: Irinotecan · Drug: Bevacizumab · Drug: Cetuximab
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Participants
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Crossover and First Line Arm
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm A
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm C
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm C
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 32 months)
Progression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months)
Progression-free Survival (PFS) by Investigator - 1L Participants
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Time frame: From date of randomization to the date of first objectively documented disease progression or death due to any cause, whichever occurs first (Up to approximately 60 months for arm A and arm B; up to 32 months for arm C)
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC
Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)
Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants
Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From date of randomization to the date of the initial objectively documented tumor progression, or the date of initiation of subsequent therapy, whichever occurs first (Up to approximately 60 months)
Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC
Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
Time frame: From randomization to the date of death due to any cause (Up to approximately 60 months)
Overall Survival (OS) - 1L Participants
Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
Time frame: From randomization to the date of death due to any cause
| Milestone | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|---|
| Started | 353 | 354 | 132 |
| Completed | 351 | 352 | 115 |
| Not completed | 2 | 2 | 17 |
| Withdrew: Withdrawal by subject | 0 | 0 | 9 |
| Withdrew: Participant no longer meets study criteria | 2 | 1 | 2 |
| Withdrew: Other reasons | 0 | 1 | 6 |
| Milestone | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|---|
| Started | 351 | 352 | 115 |
| Crossover to arm b | 0 | 0 | 60 |
| Completed | 137 | 159 | 0 |
| Not completed | 214 | 193 | 115 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Death | 2 | 4 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 | 0 |
| Withdrew: Other reasons | 5 | 13 | 6 |
| Withdrew: Disease progression | 137 | 82 | 85 |
| Withdrew: Study drug toxicity | 28 | 48 | 8 |
| Withdrew: Adverse event unrelated to study drug | 28 | 22 | 6 |
| Withdrew: Maximum clinical benefit | 0 | 1 | 9 |
| Withdrew: On-going treatment | 13 | 20 | 0 |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Lines Centrally Confirmed MSI-H/dMMR | 39.26 (2.11 to NA) | NA (53.82 to NA) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm C 1L Participants Centrally Confirmed MSI-H/dMMR | NA (38.44 to NA) | 5.85 (4.37 to 7.79) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - Arm B vs. Arm A All Randomized Participants | 18.43 (9.20 to 28.16) | 54.08 (44.02 to NA) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) - 1L Randomized Participants | 44.85 (18.23 to NA) | NA (34.30 to NA) | 6.21 (4.70 to 9.00) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm A | NA (24.80 to NA) | NA (53.82 to NA) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm A | 44.29 (25.56 to NA) | NA (53.82 to NA) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Polymerase Chain Reaction (PCR) - Arm B vs. Arm C | NA (38.44 to NA) | 6.21 (4.70 to 9.03) |
BICR-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) by Blinded Independent Review Center (BICR) by Immunohistochemistry (IHC) - Arm B vs. Arm C | NA (38.44 to NA) | 6.21 (4.70 to 9.03) |
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Investigator- Arm B vs. Arm A All Lines | 22.18 (11.70 to 29.44) | 54.08 (41.17 to NA) |
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Progression-free Survival (PFS) by Investigator - Arm A and Arm B All Lines With dMMR/MSI-H mCRC | 38.14 (27.20 to NA) | NA (54.08 to NA) |
Investigator-assessed Progression-free survival (PFS) is defined as the time from the randomization date to the date of first objectively documented disease progression per RECIST 1.1 (i.e, radiologic) or death due to any cause, whichever occurs first.
Results for this outcome have not been posted.
Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.
| Percentage of participants | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - Arm A and Arm B All Lines With dMMR/MSI-H mCRC | 57.7 (51.7 to 63.5) | 70.6 (65.1 to 75.7) |
Objective Response Rate (ORR) is defined as the percentage of all randomized participants whose best overall response is either confirmed complete response (CR) or confirmed partial response (PR). CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)=At least a 20% increase in the sum of diameters of target lesions. the sum must also demonstrate an absolute increase of at least 5 mm.
| Percentage of participants | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy |
|---|---|---|---|
| Objective Response Rate (ORR) by Blinded Independent Review Center (BICR) - 1L Participants | 61.2 (53.4 to 68.5) | 72.5 (65.2 to 79.1) | 27.4 (18.2 to 38.2) |
Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
| Months | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab |
|---|---|---|
| Overall Survival (OS) - Arm B vs. Arm A All Lines With dMMR/MSI-H mCRC | NA (NA to NA) | NA (NA to NA) |
Overall Survival (OS) is defined as the time from the randomization date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.
Results for this outcome have not been posted.
Collected over Participants were assessed for all-cause mortality from their first dose to their primary completion (up to approximately 60 months). SAEs and Other AEs were assessed from first dose up to 100 days post last dose (Up to approximately 60 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nivolumab | 150/353 (42.5%) | 161/351 (45.9%) | 311/351 (88.6%) |
| Arm B: Nivolumab + Ipilimumab | 103/354 (29.1%) | 174/352 (49.4%) | 330/352 (93.8%) |
| Arm C: Chemotherapy | 62/132 (47%) | 58/115 (50.4%) | 114/115 (99.1%) |
| Crossover: Nivolumab + Ipilimumab | 24/60 (40%) | 38/60 (63.3%) | 52/60 (86.7%) |
| Event | Arm A: Nivolumab | Arm B: Nivolumab + Ipilimumab | Arm C: Chemotherapy | Crossover: Nivolumab + Ipilimumab |
|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 36/351 | 22/352 | 8/115 | 5/60 |
| Abdominal painGastrointestinal disorders | 6/351 | 7/352 | 6/115 | 1/60 |
| Intestinal obstructionGastrointestinal disorders | 9/351 | 6/352 | 6/115 | 0/60 |
| DiarrhoeaGastrointestinal disorders | 6/351 | 8/352 | 4/115 | 3/60 |
| IleusGastrointestinal disorders | 7/351 | 0/352 | 4/115 | 1/60 |
| PneumoniaInfections and infestations | 6/351 | 7/352 | 4/115 | 1/60 |
| Adrenal insufficiencyEndocrine disorders | 4/351 | 11/352 | 0/115 | 2/60 |
| HypophysitisEndocrine disorders | 3/351 | 10/352 | 0/115 | 2/60 |
| ColitisGastrointestinal disorders | 2/351 | 5/352 | 1/115 | 2/60 |
| VomitingGastrointestinal disorders | 2/351 | 3/352 | 1/115 | 2/60 |
| Event | Arm A: Nivolumab | Arm B: Nivolumab + Ipilimumab | Arm C: Chemotherapy | Crossover: Nivolumab + Ipilimumab |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 102/351 | 119/352 | 66/115 | 18/60 |
| NauseaGastrointestinal disorders | 58/351 | 72/352 | 55/115 | 15/60 |
| AstheniaGeneral disorders | 84/351 | 93/352 | 45/115 | 12/60 |
| PruritusSkin and subcutaneous tissue disorders | 81/351 | 105/352 | 6/115 | 15/60 |
| Decreased appetiteMetabolism and nutrition disorders | 46/351 | 53/352 | 33/115 | 11/60 |
| Abdominal painGastrointestinal disorders | 67/351 | 64/352 | 31/115 | 9/60 |
| VomitingGastrointestinal disorders | 38/351 | 39/352 | 27/115 | 7/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 54/351 | 70/352 | 5/115 | 14/60 |
| AnaemiaBlood and lymphatic system disorders | 71/351 | 58/352 | 26/115 | 11/60 |
| NeutropeniaBlood and lymphatic system disorders | 3/351 | 10/352 | 26/115 | 2/60 |
| Age, Continuous(Years) | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 13.76 | 60.5 ± 13.14 | 61.3 ± 14.93 | 60.5 ± 13.69 |
| Sex: Female, Male(Participants) | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy | Total |
|---|---|---|---|---|
| Female | 163 | 192 | 68 | 423 |
| Male | 190 | 162 | 64 | 416 |
| Ethnicity (NIH/OMB)(Participants) | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 34 | 32 | 11 | 77 |
| Not Hispanic or Latino | 189 | 165 | 67 | 421 |
| Unknown or Not Reported | 130 | 157 | 54 | 341 |
| Race (NIH/OMB)(Participants) | Arm A - Nivolumab Monotherapy | Arm B - Nivolumab + Ipilimumab | Arm C - Investigator's Choice Chemotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 36 | 27 | 15 | 78 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 2 | 13 |
| White | 305 | 311 | 113 | 729 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 12 | 2 | 19 |
Showing the first 100 of 157 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Aug 2019 to primary completion in Aug 2024, 60 months.
Results were first posted in Sep 2025, 1 year after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 60 months is above that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ipilimumab · Nivolumab